GALT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
GALT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Galectin Therapeutics's average Accounts Receivable for the three months ended in Sep. 2024 was $0.00 Mil. Galectin Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil.
The historical rank and industry rank for Galectin Therapeutics's Days Sales Outstanding or its related term are showing as below:
Galectin Therapeutics's Days Sales Outstanding stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00).
The historical data trend for Galectin Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galectin Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Galectin Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Days Sales Outstanding | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Galectin Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Galectin Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Galectin Therapeutics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Galectin Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
Galectin Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:
Days Sales Outstanding (Q: Sep. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jun. 2024 ) | + | Accounts Receivable (A: Sep. 2024 )) | / | count ) | / | Revenue (A: Sep. 2024 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galectin Therapeutics (NAS:GALT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Galectin Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Harold H. Shlevin | director, officer: Chief Executive Officer | C/O GALECTIN THERAPEUTICS, INC., 4690 PEACHTREE INDUSTRIAL BLVD, STE. 240, NORCROSS GA 30071 |
Zordani Richard A. Jr. | director | 467 N. COUNTRY RIDGE CT., LAKE ZURICH IL 60047 |
Kary Eldred | director | 2121 RINGWOOD AVENUE, SAN JOSE CA 95131 |
Kevin D Freeman | director | 712 LAKEWAY DRIVE, KELLER TX 76248 |
Joel Lewis | director | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Jack W Callicutt | officer: Chief Financial Officer | 75 FIFTH STREET NW STE. 313, ATLANTA GA 30308 |
James C Czirr | director | 4908 SOUTH ASHTON COURT, SPOKANE WA 99223 |
10x Fund, L.p. | 10 percent owner | 1099 FOREST LAKE TERRACE, NICEVILLE FL 32578 |
Elissa J. Schwartz | director | 235 SW CHURCH ST., PULLMAN WA 99163 |
Gilbert F Amelio | director | 5835 STRASBOURG COURT, ---, RENO NV 89511 |
Richard E Uihlein | director, 10 percent owner | 12575 ULINE DRIVE, PLEASANT PRAIRIE WI 53158 |
Pol F Boudes | officer: Chief Medical Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Marc Rubin | director | C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080 |
Gilbert S Omenn | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
Peter G Traber | director, officer: President and CEO | 430 THAMER LANE, HOUSTON TX 77025 |
From GuruFocus
By GuruFocus Research • 11-13-2023
By Marketwired • 11-03-2023
By Marketwired • 09-30-2024
By GuruFocus Research • 02-07-2024
By GlobeNewswire • 09-13-2023
By Marketwired • 05-15-2024
By Marketwired • 09-07-2023
By GuruFocus Research • 02-07-2024
By GuruFocus Research • 02-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.